Neurological adverse effects caused by cytotoxic and targeted therapies

Nature Reviews Clinical Oncology

Volumn 6, Issue 10, 2009, Pages 596-603

  Schiff, David ^a   Wen, Patrick Y ^b   van den Bent, Martin J ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBAMAZEPINE; CLOFARABINE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOCETAXEL; ENOXAPARIN; FLUOROURACIL; GABAPENTIN; GLUCONATE CALCIUM; GLUTATHIONE; IMATINIB; IXABEPILONE; LENALIDOMIDE; MAGNESIUM SULFATE; MELPHALAN; METHOTREXATE; NELARABINE; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; WARFARIN;

ACUTE BRAIN DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; ANAPLASTIC CARCINOMA; ARACHNOIDITIS; ATAXIA; AUTONOMIC NEUROPATHY; BACKACHE; BEDTIME DOSAGE; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CANCER; COLORECTAL CANCER; COMA; CONFUSION; CONSCIOUSNESS; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOMA; HALLUCINATION; HAND PARESTHESIA; HEADACHE; HEMATOLOGIC MALIGNANCY; HOARSENESS; HUMAN; HYPERTENSION; INFECTION; KIDNEY CANCER; LEUKOENCEPHALOPATHY; LIMB WEAKNESS; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MENINGISM; MENINGITIS; METASTASIS; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOGLOBINURIA; MYOKYMIA; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PTOSIS; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; RHABDOMYOLYSIS; SEIZURE; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SUBDURAL HEMATOMA; T CELL LEUKEMIA; TREMOR; TUMOR BLEEDING; URINE RETENTION; VISUAL FIELD DEFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DRUG APPROVAL; EPOTHILONES; HUMANS; INDOLES; NEOPLASMS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PIPERAZINES; PYRAZINES; PYRIMIDINES; PYRROLES; TUBULIN MODULATORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70349972023     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.128     Document Type: Review

References (91)

1. Posner, J. B. Neurologic Complications of Cancer (F. A. Davis Company, Philadelphia, 1995).
2. Schiff, D. & Wen, P. Y. Cancer Neurology in Clinical Practice (Humana Press, Totowa, 2002).
3. Roche, H. et al. Phase ii clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25, 3415-3420 (2007).
4. Perez, E. A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407-3414 (2007).
5. Aghajanian, C. et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol. 25, 1082-1088 (2007).
6. Lee, J. J. et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J. Clin. Oncol. 24, 2084-2091 (2006).
7. Galsky, M. D. et al. Multi-institutional randomized phase ii trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J. Clin. Oncol. 23, 1439-1446 (2005).
8. Rook, J., Rosser, T., Fangusaro, J. & Finlay, J. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr. Blood Cancer 50, 699-700 (2008).
9. Ziske, C. G. et al. Acute transient encephalopathy after paclitaxel infusion: Report of three cases. Ann. Oncol. 13, 629-631 (2002).
10. Nieto, Y. et al. Acute encephalopathy: A new toxicity associated with high-dose paclitaxel. Clin. Cancer Res. 5, 501-506 (1999).
11. Ibrahim, N. K. et al. Multicenter phase II trial of ABi-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23, 6019-6026 (2005).
12. Gradishar, W. J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
13. ibrahim, N. K. et al. Phase I and pharmacokinetic study of ABi-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044 (2002).
14. Kelly, H. & Goldberg, R. M. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J. Clin. Oncol. 23 4553-4560 (2005).
15. Schmoll, H.-J. & Cassidy, J. integrating oxaliplatin into the management of colorectal cancer. Oncologist 6, 24-28 (2001).
16. Lehky, T. J., Leonard, G. D., Wilson, R. H., Grem, J. L. & Floeter, M. K. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle Nerve 29, 387-392 (2004).
17. Grothey, A. Oxaliplatin-safety profile: Neurotoxicity. Semin. Oncol. 30, 5-13 (2003).
18. Wilson, R. H. et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 20, 1767-1774 (2002).
19. Cersosimo, R. J. Oxaliplatin-associated neuropathy: A review. Ann. Pharmacother. 39, 128-135 (2005).
20. Krishnan, A. V., Goldstein, D., Friedlander, M. & Kiernan, M. C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32, 51-60 (2005).
21. Taieb, S., Trillet-Lenoir, V., Rambaud, L., Descos, L. & Freyer, G. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94, 2434-2440 (2002).
22. Gilles-Amar, V. et al. Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in metastatic colorectal cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 18 246a (1999).
23. von Delius, S. et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Invest. New Drugs 25, 173-180 (2007).
24. Argyriou, A. A. et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67 2253-2255 (2006).
25. Cascinu, S. et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 20, 3478-3483 (2002).
26. Grolleau, F. et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85, 2293-2297 (2001).
27. Gamelin, L. et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 10 4055-4061 (2004).
28. Hochster, H. S., Grothey, A. & Childs, B. H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J. Clin. Oncol. 25, 4028-4029 (2007).
29. Hochster, H. S. & Grothey, A. In reply. J. Clin. Oncol. 26, 1189 (2008).
30. Nikcevich, D. A. et al. Effect of intravenous calcium and magnesium (iV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7 [abstract]. ASCO Meeting Abstracts 26, 4009 (2008).
31. Patel, M., McCully, C., Godwin, K. & Balis, F. M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J. Neurooncol. 61, 203-207 (2003).
32. de Wit, M. C., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. & van den Bent, M. J. immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63, 535-537 (2004).
33. Brandes, A. A. et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26, 2192-2197 (2008).
34. Taal, W. et al. incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113, 405-410 (2008).
35. Mason, W. P. et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr. Oncol. 14, 110-117 (2007).
36. Berg, S. L. et al. Phase ii study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J. Clin. Oncol. 23 3376-3382 (2005).
37. Cohen, M. H., Johnson, J. R., Justice, R. & Pazdur, R. FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 13, 709-714 (2008).
38. Berg, S. L. et al. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother. Pharmacol. 59, 743-747 (2007).
39. Berg, S. L. et al. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin. Cancer Res. 11, 5981-5983 (2005).
40. Faderl, S. et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112, 1638-1645 (2008).
41. Kantarjian, H. M., Jeha, S., Gandhi, V., Wess, M. & Faderl, S. Clofarabine: Past, present, and future. Leuk. Lymphoma 48, 1922-1930 (2007).
42. Glantz, M. J. et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110-3116 (1999).
43. Jabbour, E. et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with highdose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109, 3214-3218 (2007).
44. Adams, J. The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360 (2004).
45. Richardson, P. G. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24, 3113-3120 (2006).
46. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
47. Oaklander, A. L. et al. Multiple myeloma polyneuropathy before and after initial chemotherapy with single-agent bortezomib. In 131st Annual Meeting of the American Neurological Association (Chicago, IL, 2006).
48. Richardson, P. G. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110, 3557-3560 (2007).
49. Cavaletti, G. et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol. 204, 317-325 (2007).
50. Vredenburgh, J. J. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
51. Cloughesy, T. F. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. ASCO Meeting Abstracts 26, 2010b (2008).
52. Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2008).
53. Glusker, P., Recht, L. & Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980-982 (2006).
54. Ozcan, C., Wong, S. J. & Hari, P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980-982 (2006).
55. Allen, J. A., Adlakha, A. & Bergethon, P. R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol. 63, 1475-1478 (2006).
56. Koopman, M., Muller, E. W. & Punt, C. J. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: Report of a case. Dis. Colon Rectum 51, 1425-1426 (2008).
57. Govindarajan, R., Adusumilli, J., Baxter, D. L., El-Khoueiry, A. & Harik, S. I. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J. Clin. Oncol. 24, e48 (2006).
58. Kapiteijn, E., Brand, A., Kroep, J. & Gelderblom, H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol. 18, 1745-1747 (2007).
59. Martin, G., Bellido, L. & Cruz, J. J. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J. Clin. Oncol. 25, 3559 (2007).
60. Gijtenbeek, J. M., van den Bent, M. J. & Vecht, C. J. Cyclosporine neurotoxicity: A review. J. Neurol. 246, 339-346 (1999).
61. van der Veldt, A. A., van den Eertwegh, A. J., Hoekman, K., Barkhof, F. & Boven, E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann. Oncol. 18, 1747-1750 (2007).
62. Kilickap, S., Abali, H. & Celik, I. Bevacizumab, bleeding, thrombosis, and warfarin. J. Clin. Oncol. 21, 3542 (2003).
63. Johnson, D. H. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004).
64. Carden, C. P., Larkin, J. M. & Rosenthal, M. A. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 10 624-630 (2008).
65. Pouessel, D. & Culine, S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur. Urol. 53, 376-381 (2008).
66. Nghiemphu, P. L., Green, R. M., Pope, W. B., Lai, A. & Cloughesy, T. F. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 10, 355-360 (2008).
67. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
68. Deininger, M. W., O'Brien, S. G., Ford, J. M. & Druker, B. J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21, 1637-1647 (2003).
69. Penel, N., Blay, J. Y. & Adenis, A. imatinib as a possible cause of severe rhabdomyolysis. N. Engl. J. Med. 358, 2746-2747 (2008).
70. Song, K. W. et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk. Lymphoma 45, 1633-1636 (2004).
71. Pollack, i. F. et al. Phase i trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol. 9, 145-160 (2007).
72. Wen, P. Y. et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 12, 4899-4907 (2006).
73. Ghobrial, I. M. & Rajkumar, S. V. Management of thalidomide toxicity. J. Support. Oncol. 1, 194-205 (2003).
74. Glasmacher, A. et al. A systematic review of phase-ii trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 132, 584-593 (2006).
75. Plasmati, R. et al. Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69, 573-581 (2007).
76. Cavaletti, G. et al. Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study. Neurology 62, 2291-2293 (2004).
77. Chaudhry, V. et al. Thalidomide-induced neuropathy. Neurology 59, 1872-1875 (2002).
78. Briani, C. et al. Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus. Neurology 62, 2288-2290 (2004).
79. Mileshkin, L. et al. Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. J. Clin. Oncol. 24, 4507-4514 (2006).
80. Tosi, P. et al. Neurological toxicity of long-term (1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. 74, 212-216 (2005).
81. Bastuji-Garin, S. et al. incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients. J. Invest. Dermatol. 119, 1020-1026 (2002).
82. Offidani, M. et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy. Eur. J. Haematol. 72, 403-409 (2004).
83. Sharma, R. A. et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase i clinical trial of three dosing schedules in patients with solid malignancies. Eur. J. Cancer 42, 2318-2325 (2006).
84. Richardson, P. G. et al. immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100, 3063-3067 (2002).
85. Fine, H. A. et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin. Cancer Res. 13, 7101-7106 (2007).
86. Dimopoulos, M. A., Kastritis, E. & Rajkumar, S. V. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22, 1343-1353 (2008).
87. Terpos, E. et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22, 2247-2256 (2008).
88. Pineda-Roman, M. et al. VTD combination therapy with bortezomib-thalidomide- dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22, 1419-1427 (2008).
89. Palumbo, A. et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109, 2767-2772 (2007).
90. Ciolli, S. et al. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br. J. Haematol. 141, 814-819 (2008).
91. Richardson, P. et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study [abstract]. Blood (ASH Annual Meeting Abstracts) 110, 2714 (2007).